Vertex Pharmaceuticals
VRTXInstitutional ownership · Q2 2026
Institutional holders
1,768
+62 (+3.6%) vs Q1 2026
Reported value
$119.7B
+12.8% vs Q1 2026
Shares held
241.5M
+3.7M shares
Quarter
Q2 2026
Period ended Jun 30, 2026
1,768 institutional managers reported holding 241,496,765 shares worth $119,745,187,199 on Form 13F for Q2 2026, against 1,706 in Q1 2026. Share positions on CUSIP 92532FAA8 only; option legs and principal-amount lines are not counted.
Top 25 institutional holders · Q2 2026
| # | Manager | Shares | Value | % of portfolio | Change | Position page |
|---|---|---|---|---|---|---|
| 1 | Capital World Investors | 26,115,014 | $13.0B | 1.53% | +746.9K | Position |
| 2 | BlackRock Inc | 24,109,373 | $12.0B | 0.18% | +139.9K | Position |
| 3 | Capital Research Global Investors | 19,490,637 | $9.7B | 1.35% | -1.6M | Position |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 16,580,713 | $8.2B | 0.18% | +67.9K | Position |
| 5 | STATE STREET CORPORATION | 11,871,459 | $5.9B | 0.17% | +141.3K | Position |
| 6 | Invesco Ltd | 8,043,052 | $4.0B | 0.32% | +150.4K | Position |
| 7 | JPMorgan Chase & Co | 6,517,600 | $3.3B | 0.18% | -515.6K | Position |
| 8 | GEODE CAPITAL MANAGEMENT LLC | 6,017,848 | $3.0B | 0.16% | -121.8K | Position |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,878,987 | $2.4B | 0.11% | -266.6K | Position |
| 10 | Capital International Investors | 4,695,144 | $2.3B | 0.48% | -430.9K | Position |
| 11 | LOOMIS SAYLES & CO L P | 3,920,953 | $1.9B | 2.44% | -82.9K | Position |
| 12 | FRANKLIN RESOURCES INC | 3,347,253 | $1.7B | 0.36% | +2.8M | Position |
| 13 | WELLINGTON MANAGEMENT GROUP LLP | 3,247,658 | $1.6B | 0.28% | +35.1K | Position |
| 14 | MORGAN STANLEY | 3,242,139 | $1.6B | 0.09% | +53.3K | Position |
| 15 | UBS ASSET MANAGEMENT AMERICAS INC | 3,086,683 | $1.5B | 0.28% | +29.3K | Position |
| 16 | Bank of America Corporation | 3,039,178 | $1.5B | 0.1% | +161.0K | Position |
| 17 | JENNISON ASSOCIATES LLC | 2,998,530 | $1.5B | 0.89% | +258.5K | Position |
| 18 | NORGES BANK | 2,971,681 | $1.5B | 0.15% | New | Position |
| 19 | ALLIANCEBERNSTEIN L P | 3,019,315 | $1.3B | 0.45% | -891.5K | Position |
| 20 | AMERIPRISE FINANCIAL INC | 2,604,822 | $1.3B | 0.26% | -28.7K | Position |
| 21 | NORTHERN TRUST CORPORATION | 2,486,478 | $1.2B | 0.14% | -77.8K | Position |
| 22 | The Goldman Sachs Group Inc | 2,481,761 | $1.2B | 0.11% | +63.9K | Position |
| 23 | Clearbridge Investments LLC | 2,342,915 | $1.2B | 0.96% | -358.1K | Position |
| 24 | VICTORY CAPITAL MANAGEMENT INC | 2,173,152 | $1.1B | 0.61% | +284.6K | Position |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,041,282 | $1.0B | 0.13% | +120.4K | Position |
Values as reported on each manager's Q2 2026 Form 13F. Change is in shares against the manager's prior-quarter filing.
13F holders by quarter
| Quarter | Holders | Shares | Value |
|---|---|---|---|
| Q2 2026 | 1,768 +62 | 241.5M | $119.7B |
| Q1 2026 | 1,706 +28 | 237.8M | $106.1B |
| Q4 2025 | 1,678 +150 | 241.6M | $109.5B |
| Q3 2025 | 1,528 -36 | 232.3M | $90.8B |
| Q2 2025 | 1,564 -56 | 240.9M | $107.2B |
| Q1 2025 | 1,620 +54 | 240.2M | $116.5B |
| Q4 2024 | 1,566 +17 | 236.5M | $95.2B |
| Q3 2024 | 1,549 +2 | 235.1M | $109.1B |
| Q2 2024 | 1,547 +53 | 235.1M | $109.9B |
| Q1 2024 | 1,494 +54 | 235.8M | $98.0B |
| Q4 2023 | 1,440 +160 | 235.9M | $95.7B |
| Q3 2023 | 1,280 -7 | 235.9M | $82.0B |
| Q2 2023 | 1,287 +80 | 237.9M | $83.3B |
| Q1 2023 | 1,207 -19 | 239.8M | $74.9B |
| Q4 2022 | 1,226 +118 | 237.1M | $68.3B |
| Q3 2022 | 1,108 +28 | 237.0M | $68.4B |
| Q2 2022 | 1,080 +51 | 235.1M | $66.0B |
| Q1 2022 | 1,029 +46 | 234.1M | $60.8B |
| Q4 2021 | 983 +103 | 230.0M | $50.4B |
| Q3 2021 | 880 | 231.2M | $41.8B |
Q3 2021–Q2 2026, as reported on Form 13F. Earlier quarters are in the ownership explorer below.
Across other SEC filings
Insiders · Form 4
Net insider transactions, 12 months
-$158M
0 filings with purchases ($0),
52 filings with sales ($158M)
Latest filings
- Daniel J. Brennan 2026-10-22 Award
- Bruce I Sachs 2026-10-19 Award
- Alan M Garber 2026-10-19 Award
- Grunsven Jasper Van 2026-09-10 Award
- Kristen Ambrose 2026-09-01 Award
Annual & quarterly reports
-
10-K · FY2025 Filed 2026-02-13Business · Risk Factors · Management's Discussion and Analysis
-
10-Q · Q3 FY2026 Filed 2026-11-03Management's Discussion and Analysis · Controls and Procedures · Legal Proceedings · Risk Factors
Federal lobbying
Spend, trailing 12 months
$5.1M
Through Q3 2026, from quarterly LD-2 reports
Vertex Pharmaceuticals lobbying profile
Ownership explorer
Loading ownership explorer…
Security Details
| CUSIP | 92532FAA8 |
|---|---|
| Symbol | VRTX |
| Type | Bond |
| Class | COM as filed on 13F |
| Exchange | NOT LISTED |
| Company | Vertex Pharmaceuticals |
Other securities from this issuer
| Name | Symbol | CUSIP | Type |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC | VRTX | 92532F100 | Common stock |
| VERTEX PHARMACEUTICALS INC | VRTX 3.35 10/01/15 | 92532FAN0 | Bond |
| VERTEX PHARMACEUTICALS INC | VRTX 5.75 02/15/11 * | 92532FAF7 | Bond |
| VERTEX PHARMACEUTICALS INC | VRTX 4.75 02/15/13 | 92532FAM2 | Bond |
| VERTEX PHARMACEUTICALS INC | VRTX 5 03/14/07 | 92532FAB6 | Bond |
| VERTEX PHARMACEUTICALS INC | VRTX 5 09/19/07 144A | 92532FAC4 | Bond |
| VERTEX PHARMACEUTICALS INC | VRTX 5.75 02/15/11 | 92532FAK6 | Bond |
| VERTEX PHARMACEUTICALS INC | VRTX 5 09/19/07 REGS | 92532FAD2 | Bond |
Identifier History
| Type | Value | From | To |
|---|---|---|---|
| CUSIP | 92532FAA8 | 2000-06-30 | Current |
Listing History
| Symbol | Exchange | From | To |
|---|---|---|---|
| VRTX | 2021-01-19 | Current |